Key result
Ranolazine, which selectively inhibits the late sodium current, represents a new class of anti-anginal medication for the treatment of chronic stable angina.
Ranolazine represents the first new class of anti-anginal medication approved in 25 years, offering an additional therapeutic option for chronic stable angina by targeting cellular sodium and calcium homeostasis.
No takes yet. Share an insight, caveat, or question.
May expand angina options via novel mechanism; leaves open comparative effectiveness versus established agents.
C Conti (2007) conducted a review in Chronic stable angina. Ranolazine was evaluated. Ranolazine, which selectively inhibits the late sodium current, represents a new class of anti-anginal medication for the treatment of chronic stable angina.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: